open access

Vol 78, No 4 (2020)
Review paper
Published online: 2020-04-24
Get Citation

What should a cardiologist know about coronavirus disease 2019?

Grzegorz Sławiński, Ewa Lewicka
DOI: 10.33963/KP.15302
·
Kardiol Pol 2020;78(4):278-283.

open access

Vol 78, No 4 (2020)
Review article
Published online: 2020-04-24

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the cause of coronavirus disease 2019 (COVID‑19). The most common symptoms of COVID‑19 are: fever (81.8%–100%), cough (46.3%–86.2%), myalgia and fatigue (11%–50%), expectoration (4.4%–72%), and dyspnea (18.6%–59%). The most common laboratory abnormalities in COVID‑19 include decreased lymphocyte count (35%–82.1%), thrombocytopenia (17%–36.2%), elevated serum C‑reactive protein (60.7%–93%), lactate dehydrogenase (41%–76%), and D‑dimer concentrations (36%–46.4%). Among comorbidities in patients with COVID‑19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID‑19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID‑19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated N‑terminal pro-B‑type natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the life‑threatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID‑19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID‑19 symptoms, possible clinical manifestations, complications, and recommended treatment.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the cause of coronavirus disease 2019 (COVID‑19). The most common symptoms of COVID‑19 are: fever (81.8%–100%), cough (46.3%–86.2%), myalgia and fatigue (11%–50%), expectoration (4.4%–72%), and dyspnea (18.6%–59%). The most common laboratory abnormalities in COVID‑19 include decreased lymphocyte count (35%–82.1%), thrombocytopenia (17%–36.2%), elevated serum C‑reactive protein (60.7%–93%), lactate dehydrogenase (41%–76%), and D‑dimer concentrations (36%–46.4%). Among comorbidities in patients with COVID‑19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID‑19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID‑19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated N‑terminal pro-B‑type natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the life‑threatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID‑19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID‑19 symptoms, possible clinical manifestations, complications, and recommended treatment.

Get Citation
About this article
Title

What should a cardiologist know about coronavirus disease 2019?

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 78, No 4 (2020)

Article type

Review paper

Pages

278-283

Published online

2020-04-24

Page views

404

Article views/downloads

341

DOI

10.33963/KP.15302

Bibliographic record

Kardiol Pol 2020;78(4):278-283.

Authors

Grzegorz Sławiński
Ewa Lewicka

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl